Emmanuelle Bourbouloux

Author

Institut Génétique Nantes Atlantique

Also Known As

E Bourbouloux, E. Bourbouloux, Emmanuelle BOURBOULOUX, Emmanuelle Bourbouloux

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Institut Génétique Nantes Atlantique Inserm Institut de Cancérologie de l'Ouest Institut Bergonié Institut Jean Godinot

About

Emmanuelle Bourbouloux is an author at Institut Génétique Nantes Atlantique specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.1K
2	Health Sciences	7	7	874
3	Pathology	3	3	170
4	Obstetrics	2	2	60
5	Geriatrics	1	1	35

Emmanuelle Bourbouloux

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography Caroline Rousseau, Anne Devillers, Christine Sagan, Journal of Clinical Oncology	2006	310
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial Xavier Pivot, Gilles Romieu, Marc Debled, The Lancet Breast OncologyOncologyEarly Breast CancerRandomised TrialBreast Cancer	2019	125
Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours M. Campone, Vincent Lévy, Emmanuelle Bourbouloux, British Journal of Cancer	2009	97
Brown fat in breast cancer patients: analysis of serial 18F-FDG PET/CT scans Caroline Rousseau, Emmanuelle Bourbouloux, L. Campion, European Journal of Nuclear Medicine and Molecular Imaging Medical ImagingBreast Cancer PatientsMedicineCancer DetectionBrown Fat	2006	90
Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas Delphine Loussouarn, L. Campion, Christine Sagan, British Journal of Cancer	2008	81
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer Claire Falandry, Frédérique Rousseau, Marie‐Ange Mouret‐Reynier, JAMA Oncology	2021	78
Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial Étienne Brain, C. Mertens, Véronique Girre, Critical Reviews in Oncology/Hematology Breast OncologyPhase IiMedicinePharmacologyClinical Trials	2010	59
Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy Mario Campone, H. Cortés-Funes, Daniel Vorobiof, British Journal of Cancer	2006	53
Oxaliplatin‐based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients Jean‐Sébastien Frenel, Christophe Leux, Luc Pouplin, Journal of Surgical Oncology	2010	48

Page 1